Surgical Endoscopy

, Volume 25, Issue 8, pp 2756–2757 | Cite as

Mediastinal lymphadenopathy: assessing clinical utility of EUS-FNA

  • Charalambos BatsisEmail author


Lymph Node Positron Emission Tomography Perforation Mediastinal Lymph Node System Biology Approach 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



C. Batsis has no conflicts of interest or financial ties to disclose.


  1. 1.
    Hirdes MM, Schwartz MP, Tytgat KM, Schlösser NJ, Sie-Go DM, Brink MA, Oldenburg B, Siersema PD, Vleggaar FP (2010) Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers. Surg Endosc 24(9):2260–2267PubMedCrossRefGoogle Scholar
  2. 2.
    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995 author reply 1995–1996PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726PubMedCrossRefGoogle Scholar
  4. 4.
    Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476PubMedCrossRefGoogle Scholar
  5. 5.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555PubMedCrossRefGoogle Scholar
  6. 6.
    Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22(5):1402–1404PubMedCrossRefGoogle Scholar
  7. 7.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRefGoogle Scholar
  9. 9.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRefGoogle Scholar
  10. 10.
    Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Pers Med 7(4):347–350CrossRefGoogle Scholar
  11. 11.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH (2010) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. doi: 10.1038/tpj.2010.81
  16. 16.
    Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15PubMedCrossRefGoogle Scholar
  17. 17.
    Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Dev 7(6):723–726CrossRefGoogle Scholar
  18. 18.
    Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRefGoogle Scholar
  24. 24.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital of Ioannina, School of MedicineIoanninaGreece

Personalised recommendations